Inflammatory breast cancer

Overview

Inflammatory breast cancer (IBC) is a rare but aggressive form of invasive breast cancer in which cancer cells spread into the lymphatic vessels of the skin covering the breast. As these tiny drainage channels become blocked by tumour cells, fluid builds up in the breast tissue, producing the characteristic appearance that gives the disease its name: a breast that looks red, swollen, warm and inflamed.

Unlike the majority of breast cancers, IBC often does not form a distinct lump. Instead, it announces itself through rapid, visible changes to the skin and shape of the breast — changes that are frequently mistaken for an infection such as mastitis. This misunderstanding can delay diagnosis, which is why awareness of the condition is so important. IBC grows and spreads quickly, tends to be diagnosed at a more advanced stage than other breast cancers, and requires a different sequence of treatments. However, modern combined therapy has significantly improved outcomes, and many people treated today respond well and live for years beyond their diagnosis.

Key facts at a glance

What Is Inflammatory Breast Cancer and How Does It Develop?

All breast cancers begin when cells in the breast acquire damage to their DNA and start multiplying uncontrollably. In IBC — which is usually a form of invasive ductal carcinoma with particularly aggressive behaviour — the cancer cells invade the dermal lymphatic vessels, the small channels within the skin that normally drain lymph fluid away from the breast.

When clumps of tumour cells (called tumour emboli) plug these vessels, lymph fluid cannot drain properly. The result is a rapid build-up of fluid in the breast, causing swelling, redness, warmth and thickening of the skin. This is why the breast looks inflamed even though no infection or injury is present — the name describes the appearance, not the cause.

The underlying reason some breast cancers behave this way while others form discrete lumps is not fully understood. Research shows that IBC tumours have distinct biological features, including high activity of genes involved in blood- and lymph-vessel formation (angiogenesis and lymphangiogenesis), which helps the cancer spread through the skin and beyond. Compared with other breast cancers, IBC is:

• More often high-grade (fast-growing cells that look very abnormal under the microscope);
• More often hormone receptor–negative (lacking oestrogen and progesterone receptors);
• More often HER2-positive (up to roughly half of cases), which actually opens the door to effective targeted anti-HER2 drugs.

The exact trigger for the original DNA damage is unknown, and in most cases IBC is not directly inherited, although a family history of breast cancer can raise overall risk, as it does for other types of breast cancer.

Who Gets Inflammatory Breast Cancer? Risk Factors

Anyone with breast tissue can develop IBC, but research has identified several groups at higher risk:

• Sex: The overwhelming majority of cases occur in women, but IBC can, rarely, develop in men.
• Age: IBC tends to be diagnosed at a younger age than other breast cancers — frequently in women in their 40s and 50s, and it can occur in women under 40.
• Ethnicity: Studies, particularly from the United States, show higher rates in Black women, who also tend to be diagnosed younger and face poorer outcomes on average.
• Body weight: Being overweight or obese is one of the most consistently identified risk factors for IBC.
• Breast density: Having dense breast tissue may increase risk and can also make the disease harder to detect on mammograms.
• Family history: A personal or family history of breast cancer raises risk in general terms.

Having one or more of these factors does not mean a person will develop IBC — many patients have no identifiable risk factors at all.

How Does Inflammatory Breast Cancer Look?

Because a palpable lump is often absent, the appearance of the breast is the most important clue to IBC. The visual changes usually come on quickly — over a period of weeks — and typically affect one breast only. Healthcare professionals generally look for redness covering at least one-third of the breast, together with swelling and skin thickening, before considering the diagnosis.

Typical visible features include:

• Redness or discolouration: This can range from a faint pink flush to a deep red, bruise-like purple, or a rash resembling sunburn, hives or insect bites. On darker skin tones, redness may be subtle and the breast may instead look darker, dusky or purplish, making changes in texture and warmth especially important to notice.
• “Peau d’orange” (orange-peel skin): A hallmark sign. Swelling tightens the skin while the hair follicles remain anchored, so the surface develops pits and dimples resembling the peel of an orange, often with visibly enlarged pores.
• Enlargement and asymmetry: One breast may suddenly become noticeably larger, heavier and fuller than the other — some women report going up a bra-cup size within weeks.
• Tight, shiny, firm skin: The skin may look stretched and glossy, and the breast can feel unusually hard, dense or rigid.
• Ridges, welts or thickened patches: Raised areas or hive-like plaques may appear on the breast surface.
• Nipple changes: The nipple may become flattened or pulled inward (inverted), or develop crusting, scaling or an unusual discharge.
• Visible lymph-node swelling: Lumps may become apparent in the armpit or above or below the collarbone, where cancer often spreads early.

Because the signs mimic common conditions, people sometimes browse photographs online and dismiss their own symptoms — or worry unnecessarily. Images cannot confirm or exclude IBC: any sudden change in the appearance of a breast should be examined by a doctor, ideally a breast specialist.

Symptoms of Inflammatory Breast Cancer

The symptoms of IBC reflect the same process that causes its appearance — lymphatic blockage and rapid tumour growth — and they characteristically develop over weeks rather than months or years. Onset within three to six months is part of how doctors define the disease.

Main symptoms

• Rapid increase in the size of one breast — one of the earliest and most telling signs
• Redness, flushing or discolouration covering a third or more of the breast
• Warmth or heat in the affected breast, sometimes noticeably hotter to the touch
• Swelling (oedema) with a feeling of tightness or fullness
• Thickened or pitted skin (peau d’orange)
• Heaviness, aching, burning or tenderness in the breast
• Persistent itching of the breast skin
• Nipple changes — inversion, flattening, crusting or discharge
• A sensation of firmness or hardness throughout the breast rather than a single lump
• Swollen lymph nodes under the arm or near the collarbone
• Occasionally, a lump or thickened area may be felt, although this is not the norm

Important things to know about IBC symptoms

• Fever is usually absent. Despite looking “inflamed”, IBC is not an infection, so it rarely causes the fever and general unwellness seen with mastitis.
• Symptoms can masquerade as mastitis or a breast abscess, especially in younger or breastfeeding women. A crucial rule of thumb: if a suspected breast infection does not improve within 1–2 weeks of antibiotics, further investigation with imaging and possibly a biopsy is essential.
• Symptoms may fluctuate slightly day to day, but the overall trend is progression. Waiting to see whether changes settle on their own can cost valuable time.

IBC versus breast infection — quick comparison

How IBC Differs from Other Breast Cancers

How Is Inflammatory Breast Cancer Diagnosed?

Diagnosing IBC combines clinical examination, imaging and tissue sampling. Because around one-third of patients already have cancer spread (metastasis) at diagnosis, a full staging work-up is standard.

1. Physical examination and history. The doctor assesses how quickly symptoms arose and how much of the breast is involved. International expert consensus defines IBC by:

• A rapid onset of signs and symptoms (within a maximum of six months);
• Redness and/or swelling involving at least one-third of the breast;
• Confirmation of invasive cancer on biopsy.

2. Imaging:

• Diagnostic mammogram — may reveal skin thickening, increased density or a mass, but can appear deceptively normal;
• Ultrasound of the breast and armpit — useful for identifying biopsy targets and affected lymph nodes;
• MRI — sometimes used to map the extent of disease when other imaging is unclear.

3. Biopsy:

• A core needle biopsy of breast tissue confirms invasive cancer;
• A skin punch biopsy is often performed; finding tumour cells inside the skin’s lymph vessels (dermal lymphatic invasion) strongly supports the diagnosis, though it is not strictly required if the clinical picture is classic.

4. Tumour profiling: The biopsy tissue is tested for oestrogen (ER) and progesterone (PR) receptors and HER2 status, which guide treatment choices.

5. Staging scans: CT scans of the chest, abdomen and pelvis, a bone scan or a PET-CT scan are performed to look for spread to other organs.

Staging of Inflammatory Breast Cancer

IBC is never an “early-stage” cancer by formal staging. The invasion of skin lymphatics automatically classifies the tumour as T4d, meaning the disease is at least stage IIIB even when nodes are clear.

Treatment of Inflammatory Breast Cancer

IBC demands a carefully sequenced, multimodal (combined) approach, ideally at a centre experienced with the disease. Operating first is avoided because the widespread skin involvement makes complete removal unlikely at the outset; shrinking the disease with drug therapy first gives the best chance of success.

The standard treatment sequence

1. Chemotherapy first (neoadjuvant therapy).

Treatment typically begins with several months of combination chemotherapy — commonly anthracycline- and taxane-based regimens — to shrink the tumour, calm the skin changes and begin treating any microscopic spread. If the tumour is HER2-positive, targeted antibodies such as trastuzumab and pertuzumab are added, which has dramatically improved outcomes in this group. In selected high-risk cases, immunotherapy (e.g., pembrolizumab) may also be incorporated.

2. Surgery.

Once disease control is achieved, the standard operation is a modified radical mastectomy — removal of the entire breast along with the lymph nodes under the arm (axillary lymph node dissection).

• Breast-conserving surgery (lumpectomy) is not recommended, because the disease is spread throughout the breast skin and lymphatics rather than confined to one spot.
• Sentinel lymph node biopsy (removing only the first draining nodes) is generally not accurate enough in IBC.
• Breast reconstruction is usually delayed until after radiotherapy and an appropriate recovery period.

3. Radiation therapy.

After surgery, radiotherapy is delivered to the chest wall and surrounding lymph-node regions (including above the collarbone) to destroy remaining cancer cells. Some specialist centres use intensified schedules, such as twice-daily treatments, for higher-risk disease.

4. Ongoing (adjuvant) systemic therapy.

Depending on tumour biology and how well the cancer responded, further treatment may include:

• Hormone (endocrine) therapy — tamoxifen or aromatase inhibitors, often for 5–10 years, if the tumour is hormone receptor–positive;
• Completion of anti-HER2 therapy to a total of about one year;
• Additional drugs for patients with residual disease after surgery, such as capecitabine, trastuzumab emtansine (T-DM1), PARP inhibitors for those with inherited BRCA mutations, or continuation of immunotherapy.

Summary of treatment modalities

For stage IV disease, systemic (body-wide) therapy is the mainstay, with surgery or radiotherapy used selectively to control the breast disease or relieve symptoms.

Prognosis and Survival

IBC has historically carried one of the most serious prognoses of any breast cancer: before chemotherapy became standard, long-term survival was rare. Today the picture is considerably brighter, though outcomes remain below those of non-inflammatory breast cancers.

• Reported 5-year survival rates cluster around 40–55%, with wide variation between studies; patients with stage III disease who complete full trimodality therapy generally fare best.
• Outcomes have improved notably with the addition of HER2-targeted drugs and modern chemotherapy regimens.
• The response to the initial chemotherapy is one of the strongest indicators of prognosis — patients in whom no cancer remains at surgery (a complete pathological response) have substantially better long-term outcomes.
• IBC still carries a higher risk of recurrence than other breast cancers, most often within the first two to three years, which is why close follow-up is essential.

Statistics describe populations, not individuals. Many people treated for IBC today live far longer than historical averages suggest, and asking your oncology team about your own specific situation is always worthwhile.

Life During and After Treatment

Follow-up care typically involves check-ups every few months for the first two to three years, then less frequently, along with regular imaging of the remaining breast. New skin changes on the chest wall, lumps, persistent pain, unexplained cough or bone discomfort should always be reported promptly.

Possible long-term effects include lymphoedema (arm swelling) after lymph-node removal and radiotherapy — arm care, physiotherapy and prompt treatment of any arm infection help reduce this risk — as well as fatigue, menopausal symptoms from hormone therapy, and fertility effects from chemotherapy. Younger women may wish to discuss fertility preservation before treatment begins.

The emotional impact of a fast-moving, serious diagnosis should not be underestimated. Specialist nurses, counselling services and IBC-focused support organisations can make a meaningful difference, and connecting with others who have experienced the disease is often a valuable source of practical advice and hope.

Can Inflammatory Breast Cancer Be Prevented?

There is no proven way to prevent IBC, and standard screening mammograms are of limited help because the disease can arise and progress in the interval between screenings. The most effective strategies are:

• Maintaining a healthy body weight (the strongest modifiable factor linked to IBC);
• Staying physically active and limiting alcohol;
• Breastfeeding where possible, which lowers breast cancer risk overall;
• Above all, knowing what is normal for your breasts and acting quickly when something changes.

See a doctor promptly if you notice:

• One breast becoming suddenly red, warm or swollen;
• Skin that looks like orange peel, or unexplained colour change;
• A breast becoming larger, heavier or harder within weeks;
• A newly inverted nipple or unusual discharge;
• Persistent lumps in the armpit or near the collarbone;
• Any “breast infection” that fails to improve within 1–2 weeks of antibiotics.

Questions to Ask Your Care Team

• How experienced is this centre in treating inflammatory breast cancer?
• What are my tumour’s ER, PR and HER2 results, and what do they mean for my treatment?
• What is the planned order of my treatments, and why?
• Should I consider genetic testing or a clinical trial?
• How will we measure whether the chemotherapy is working?
• What side effects should I expect, and who do I contact with new symptoms?
• What will my follow-up schedule look like after treatment ends?

Key Takeaways

• IBC is a rare, fast-growing breast cancer that usually presents without a lump, through redness, swelling, warmth and orange-peel skin.
• Its symptoms can mimic infection — any suspected mastitis that does not respond quickly to antibiotics needs specialist assessment.
• Diagnosis requires rapid onset, redness over at least a third of the breast and biopsy-proven cancer; IBC is always at least stage III at diagnosis.
• Treatment follows a specific order: chemotherapy first, then mastectomy with lymph-node removal, then radiotherapy, plus targeted and hormone therapies where appropriate.
• Outcomes are serious but improving steadily, and full, timely treatment gives the best chance of long-term control.

Frequently Asked Questions

Is inflammatory breast cancer contagious or caused by an infection?

No. Despite its inflamed appearance, IBC is a cancer — it cannot be caught or passed on, and antibiotics do not treat it.

Can IBC occur during pregnancy or breastfeeding?

Yes, it can, although mastitis is far more common in these situations. Any breast changes that persist or worsen despite treatment should be investigated with imaging and, if needed, biopsy.

Is IBC hereditary?

Most cases arise sporadically without an inherited cause. However, genetic counselling and testing may still be recommended, as they inform both treatment and family risk.

Can men get inflammatory breast cancer?

Yes, although male cases are very rare. Any breast skin changes, swelling or lumps in men warrant medical assessment.

Does a normal mammogram rule out IBC?

No. IBC may not appear clearly on mammography. Persistent clinical signs should be pursued with ultrasound, MRI and biopsy even if a mammogram looks unremarkable.

References

American Cancer Society (2024) Inflammatory breast cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/inflammatory-breast-cancer.html (Accessed: 10 January 2025).

Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., Sullivan, D.C., Jessup, J.M., Brierley, J.D., Gaspar, L.E., Schilsky, R.L., Balch, C.M., Winchester, D.P., Asare, E.A., Madera, M., Gress, D.M. and Meyer, L.R. (eds) (2017) AJCC Cancer Staging Manual. 8th edn. New York: Springer.

Cancer Research UK (2023) Inflammatory breast cancer. Available at: https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types/types/inflammatory-breast-cancer (Accessed: 10 January 2025).

Dawood, S., Merajver, S.D., Viens, P., Vermeulen, P.B., Swain, S.M., Buchholz, T.A., Dirix, L.Y., Levine, P.H., Lucci, A., Krishnamurthy, S., Robertson, F.M., Woodward, W.A., Yang, W.T., Ueno, N.T. and Cristofanilli, M. (2011) ‘International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment’, Annals of Oncology, 22(3), pp. 515–523.

Giordano, S.H. and Hortobagyi, G.N. (2003) ‘Inflammatory breast cancer: clinical progress and the main problems that must be addressed’, Breast Cancer Research, 5(6), pp. 284–288.

Hance, K.W., Anderson, W.F., Devesa, S.S., Young, H.A. and Levine, P.H. (2005) ‘Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute’, Journal of the National Cancer Institute, 97(13), pp. 966–975.

Jaiyesimi, I.A., Buzdar, A.U. and Hortobagyi, G. (1992) ‘Inflammatory breast cancer: a review’, Journal of Clinical Oncology, 10(6), pp. 1014–1024.

National Cancer Institute (2024) Inflammatory breast cancer treatment (PDQ®) – Patient version. Available at: https://www.cancer.gov/types/breast/patient/breast-inflammatory-treatment-pdq (Accessed: 10 January 2025).

National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed: 10 January 2025).

Robertson, F.M., Bondy, M., Yang, W., Yamauchi, H., Wiggins, S., Kamrudin, S., Krishnamurthy, S., Le-Petross, H., Bidaut, L., Player, A.N., Barsky, S.H., Woodward, W.A., Buchholz, T., Lucci, A., Ueno, N.T. and Cristofanilli, M. (2010) ‘Inflammatory breast cancer: the disease, the biology, the treatment’, CA: A Cancer Journal for Clinicians, 60(6), pp. 351–375.

University of Texas MD Anderson Cancer Center (2024) Inflammatory breast cancer. Available at: https://www.mdanderson.org/cancer-types/inflammatory-breast-cancer.html (Accessed: 10 January 2025).

WHO Classification of Tumours Editorial Board (2019) Breast Tumours: WHO Classification of Tumours. 5th edn. Lyon: International Agency for Research on Cancer.